Clinical Evaluation of a Vascular Venous Anastomotic Connector for Minimally Invasive Connection of an Arteriovenous Graft for Hemodialysis [InterGraft Study] Save

Date Added
April 23rd, 2019
PRO Number
Pro00087325
Researcher
Vinayak Rohan

List of Studies

Silhouette
Keywords
Kidney
Summary

The InterGraft Vascular Venous Anastomotic Connector (VIG) was developed for minimally invasive anastomosis (connection) of a vein to a standard, currently sold synthetic graft for hemodialysis. The VIG is designed with a nitinol (metal) frame that is covered with a plastic material called expanded polytetrafluoroethylene, or ePTFE. The ?vein end' of the VIG is placed within the vein using a special catheter delivery system that is inserted into the vein through a small needle puncture. The ?graft end' of the VIG is fitted into the graft that is placed under the skin using standard methods. The purpose of this research study is to determine the safety and effectiveness of InterGraft Venous Anastomotic Connector for connecting a hemodialysis graft to a vein.

Institution
MUSC
Recruitment Contact
Tamara Jenkins
843-792-1851
saundert@musc.edu

Validating Cell-based Assays For ABMR After Renal Transplantation Save

Date Added
April 2nd, 2019
PRO Number
Pro00087322
Researcher
Vinayak Rohan

List of Studies

Silhouette
Keywords
Transplant
Summary

This study will evaluate a new blood test which can detect organ rejection in patients who have had a kidney transplant. Blood samples will be obtained from subjects after consent and again up to 90 days afterward to test for transplant rejection.

Institution
MUSC
Recruitment Contact
Caitlin Schaffner
843-792-7558
schaffne@musc.edu

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir. Save

Date Added
November 8th, 2016
PRO Number
Pro00058351
Researcher
Vinayak Rohan

List of Studies

Silhouette
Keywords
Drug Studies, Infectious Diseases, Transplant
Summary

This study is for patients who have received a kidney, liver, or pancreas transplant and who have developed resistant Cytomegalovirus infection. There will be two treatment groups to compare the improvement or resolution of Cytomegalovirus infection. Subjects will be randomized to receive 8 weeks of either the investigational drug, Maribavir, or physician assigned standard of care treatment.

Institution
MUSC
Recruitment Contact
Caitlin Schaffner
843-792-7558
schaffne@musc.edu

Change_preferences

-- OR --

Create_login